GI prophylaxis
Jump to navigation
Jump to search
Indications
- risk for peptic ulcer
Management
- proton pump inhibitors should be considered for patients on long-term antiplatelet therapy if:[1]
- history of peptic ulcer or gastrointestinal bleeding
- dual antiplatelet therapy or concomitant anticoagulation
- additional risk factors (age >= 60[3], glucocorticoid use, dyspepsia, or gastroesophageal reflux)
- famotidine 20 mg BID prevents peptic ulcers & erosive esophagitis in patients taking low-dose aspirin[2]
- see stress ulcer prophylaxis & stress ulceration for hospitalized patients
More general terms
More specific terms
Additional terms
References
- ↑ Jump up to: 1.0 1.1 Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ Jump up to: 2.0 2.1 Taha AS Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet, Volume 374, Issue 9684, Pages 119-125, 11 July 2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19577798
- ↑ Jump up to: 3.0 3.1 Li L, Geraghty OC, Mehta Z et al Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. Jun 13, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26227434 Free full text <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30770-5/fulltext
Diener HC Preventing major gastrointestinal bleeding in elderly patients. Lancet. Jun 13, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28622952 Free Article <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31507-6/fulltext